Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Colorcon
McKinsey
Merck
AstraZeneca
Dow

Last Updated: October 18, 2019

DrugPatentWatch Database Preview

FIRMAGON Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Firmagon, and what generic alternatives are available?

Firmagon is a drug marketed by Ferring and is included in one NDA. There are three patents protecting this drug.

This drug has one hundred and thirty patent family members in thirty-six countries.

The generic ingredient in FIRMAGON is degarelix acetate. One supplier is listed for this compound. Additional details are available on the degarelix acetate profile page.

Drug patent expirations by year for FIRMAGON
Drug Prices for FIRMAGON

See drug prices for FIRMAGON

Generic Entry Opportunity Date for FIRMAGON
Generic Entry Date for FIRMAGON*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
POWDER;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FIRMAGON

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Regeneron PharmaceuticalsPhase 2
Mark SteinPhase 2
Assistance Publique - Hôpitaux de ParisPhase 2

See all FIRMAGON clinical trials

Recent Litigation for FIRMAGON

Identify potential future generic entrants

District Court Litigation
Case NameDate
Salk Institute for Biological Studies v. Ferring Pharmaceuticals, Inc2010-12-22

See all FIRMAGON litigation

Synonyms for FIRMAGON
214766-78-6
766D786
934016-19-0
Ac-D-Nal-[D-(pCl)Phe]-D-Pal-Ser-[Aph(DHor)]-D-[Aph(Cbm)]-Leu-ILys-Pro-DAla-NH2
Acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide
AKOS030526717
AN-5181
ASP-3550
ASP3550
BDBM50102450
CHEBI:135961
CHEMBL2028987
CHEMBL415606
CS-5350
D08901
D09400
DB06699
Degarelix
Degarelix (acetate) pound>>FE 200486
Degarelix (INN/USAN)
Degarelix [USAN:INN:BAN]
Degarelix acetate
Degarelix acetate (JAN)
Degarelix monoacetate
EXT215F4ZU
FE 200486
FE-200486
FE-200486 (free base)
FE200486
FE200486 (AS ACETATE SALT)
Firmagon (TN)
Gonax
GTPL5585
HSDB 7817
HY-16168A
QC-10170
RL02641
SCHEMBL1397034
SX0XJI3A11
Uglypeptide1
UNII-EXT215F4ZU
UNII-SX0XJI3A11
Z-3147

US Patents and Regulatory Information for FIRMAGON

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-001 Dec 24, 2008 RX Yes No   Start Trial   Start Trial Y Y   Start Trial
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-002 Dec 24, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-001 Dec 24, 2008 RX Yes No   Start Trial   Start Trial   Start Trial
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-001 Dec 24, 2008 RX Yes No   Start Trial   Start Trial   Start Trial
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-002 Dec 24, 2008 RX Yes Yes   Start Trial   Start Trial   Start Trial
Ferring FIRMAGON degarelix acetate POWDER;SUBCUTANEOUS 022201-002 Dec 24, 2008 RX Yes Yes   Start Trial   Start Trial Y Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Supplementary Protection Certificates for FIRMAGON

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1003774 362 Finland   Start Trial
1003774 SPC/GB09/028 United Kingdom   Start Trial PRODUCT NAME: DEGARELIX OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT SUCH AS THE ACETATE; REGISTERED: UK EU/1/08/504/001 20090217; UK EU/1/08/504/002 20090217
1003774 91585 Luxembourg   Start Trial PRODUCT NAME: DEGARELIX, EVENTUELLEMENT UN SEL PHARMACEUTIQUEMENT ACCEPTABE, TEL QUE L'ACETATE (FIRMAGON); REG. DATE: 20090217
1003774 09C0028 France   Start Trial PRODUCT NAME: DEGARELIX, SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, EN PARTICULIER ACETATE; REGISTRATION NO/DATE IN FRANCE: EU/1/08/504/001 DU 20090217; REGISTRATION NO/DATE AT EEC: EU/1/08/504/001 DU 20090217
1003774 PA2009005,C1003774 Lithuania   Start Trial PRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
1003774 PA2009005 Lithuania   Start Trial PRODUCT NAME: DEGARELIXUM ACETAT; REGISTRATION NO/DATE: EU/1/08/504/001, 2009 02 17 EU/1/08/504/002 20090217
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Dow
Medtronic
Merck
Johnson and Johnson
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.